Key facts about INOVIQ's latest breakthrough

INOVIQ (ASX:IIQ) has successfully completed the first stage of its development program aimed at creating an exosome-based therapeutic for breast cancer. The proof-of-concept study demonstrated that engineered natural killer (NK) cells can generate exosomes capable of targeting and killing breast cancer cells. This innovative approach showed promising results, especially in triple-negative breast cancer cells.

Overview of INOVIQ's development program and future plans

INOVIQ has developed a novel method to engineer exosomes with chimeric antigen receptors (CARs), enhancing their ability to target breast cancer cells. The in vitro proof-of-concept study showed that these CAR-NK-exosomes could kill over 30% of breast cancer cells at the highest dose, demonstrating greater efficacy than previous methods. INOVIQ plans to further enhance the therapeutic activity by pre-stimulating NK cells, optimizing dosing, and conducting animal model studies. The company aims to present additional data in 2025 and is working with consultants to refine its strategies for future clinical trials. This development marks a significant milestone in INOVIQ's ambition to innovate cancer therapeutics through exosome technology.

Insights from INOVIQ's leadership

CSO Prof Gregory Rice emphasized the significant progress and potential for further enhancement of cancer-killing activity. CEO Dr. Leearne Hinch highlighted the transformational potential of the exosome therapy and the company's commitment to advancing towards clinical trials.